Law and Policy
Working to raise awareness of legal and regulatory issues that will impact the biotechnology sector.
Leadership
CO-CHAIRS
Maria Buckley, Nutter, McClennen & Fish, LLP
Nick Littlefield, Foley Hoag LLP
Patrick Waller, Wolf, Greenfield, & Sacks, P.C.
Maria Buckley, Nutter, McClennen & Fish, LLP
Nick Littlefield, Foley Hoag LLP
Patrick Waller, Wolf, Greenfield, & Sacks, P.C.
Mission
To raise awareness of legal and regulatory issues that will impact the biotechnology sector, and to provide a forum for lawyers and others at MBC member companies and firms to network and share expertise in areas of common interest, including healthcare law, intellectual property law, employment law and regulatory affairs.
United States Senator Edward M. Kennedy aptly refers to the 21st century as the "Life Sciences Century." Full integration of biotechnology in clinical research and healthcare policy will generate a multitude of discussion points on the transformation of scientific innovation into better health solutions. The Committee will keep your finger on the pulse of what's on the horizon.
Action Plan
The Law and Policy Committee strives to hold frequent educational meetings on timely and meaningful topics for member companies and firms, such as Medicare coverage and reimbursement policy. The Committee looks to partner and host programs in conjunction with other MBC committees, as appropriate.
Topics
TOPICS
Some potential topics to be discussed this year include:
Some potential topics to be discussed this year include:
- Follow on Biologics
- Cooperative Research and rDevelopment Agreements (CRADAs) and Intellectual Property Law
- Biotech Tax Credits
- Clinical Trial Disclosure
- FDA's Critical Path Initiative
- Clinical Trial Advisors in relation to the Stark Law
- Patent reform
- Drug Importation
Meetings
| Date | Event |
|---|---|
| 5/29/08 | "Drug & Device Law Update - Key Developments in Recent Case Law" |
| 6/26/08 | Injury Issues in Clinical Research |
PHONE: 617.674.5100
EMAIL: